Oxidative stress plays a role in mediating podocyte injury and proteinuria. However, the underlying mechanism remains poorly understood. In this study, we investigated the potential role of C-X-C chemokine receptor type 4 (CXCR4), the receptor for stromal cell-derived factor 1α (SDF-1α), in mediating oxidative stress-induced podocyte injury.
Results:
In mouse model of adriamycin nephropathy (ADR), CXCR4 expression was significantly induced in podocytes as early as 3 days. This was accompanied by an increased upregulation of oxidative stress in podocyte, as demonstrated by malondialdehyde assay, nitrotyrosine staining and secretion of 8-hydroxy-2′-deoxyguanosine in urine, and induction of NOX2 and NOX4, major subunits of NADPH oxidase. CXCR4 was also induced in human kidney biopsies with proteinuric kidney diseases and colocalized with advanced oxidation protein products (AOPPs), an established oxidative stress trigger. Using cultured podocytes and mouse model, we found that AOPPs induced significant loss of podocyte marker Wilms tumor 1 (WT1), nephrin, and podocalyxin, accompanied by upregulation of desmin both in vitro and in vivo. Furthermore, AOPPs worsened proteinuria and aggravated glomerulosclerosis in ADR. These effects were associated with marked activation of SDF-1α/CXCR4 axis in podocytes. Administration of AMD3100, a specific inhibitor of CXCR4, reduced proteinuria and ameliorated podocyte dysfunction and renal fibrosis triggered by AOPPs in mice. In glomerular miniorgan culture, AOPPs also induced CXCR4 expression and downregulated nephrin and WT1.
Innovation and Conclusion:
These results suggest that chemokine receptor CXCR4 plays a crucial role in mediating oxidative stress-induced podocyte injury, proteinuria, and renal fibrosis. CXCR4 could be a new target for mitigating podocyte injury, proteinuria, and glomerular sclerosis in proteinuric chronic kidney disease. Antioxid. Redox Signal. 27, 345–362.
Get full access to this article
View all access options for this article.
References
1.
AbeY, SakairiT, BeesonC, and KoppJB. TGF-β1 stimulates mitochondrial oxidative phosphorylation and generation of reactive oxygen species in cultured mouse podocytes, mediated in part by the mTOR pathway. Am J Physiol Renal Physiol, 305: F1477–F1490, 2013.
2.
BondiCD, ManickamN, LeeDY, BlockK, GorinY, AbboudHE, and BarnesJL. NAD(P)H oxidase mediates TGF-beta1-induced activation of kidney myofibroblasts. J Am Soc Nephrol, 21: 93–102, 2010.
3.
CamillaR, SuzukiH, DapraV, LoiaconoE, PeruzziL, AmoreA, GhiggeriGM, MazzuccoG, ScolariF, GharaviAG, AppelGB, TroyanovS, NovakJ, JulianBA, and CoppoR. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol, 6: 1903–1911, 2011.
4.
ChongBF and MohanC. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opin Ther Targets, 13: 1147–1153, 2009.
5.
DaiC, StolzDB, KissLP, MongaSP, HolzmanLB, and LiuY. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol, 20: 1997–2008, 2009.
6.
De ClercqE. AMD3100/CXCR4 inhibitor. Front Immunol, 6: 276, 2015.
7.
DingM, CuiS, LiC, JothyS, HaaseV, SteerBM, MarsdenPA, PippinJ, ShanklandS, RastaldiMP, CohenCD, KretzlerM, and QuagginSE. Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med, 12: 1081–1087, 2006.
8.
DoringY, PawigL, WeberC, and NoelsH. The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease. Front Physiol, 5: 212, 2014.
9.
EidAA, GorinY, FaggBM, MaaloufR, BarnesJL, BlockK, and AbboudHE. Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes, 58: 1201–1211, 2009.
10.
FornoniA, JeonJ, Varona SantosJ, CobianchiL, JaureguiA, InverardiL, MandicSA, BarkC, JohnsonK, McNamaraG, PileggiA, MolanoRD, ReiserJ, TryggvasonK, KerjaschkiD, BerggrenPO, MundelP, and RicordiC. Nephrin is expressed on the surface of insulin vesicles and facilitates glucose-stimulated insulin release. Diabetes, 59: 190–199, 2010.
11.
FukudaR, SuicoMA, KaiY, OmachiK, MotomuraK, KogaT, KomoharaY, KoyamaK, YokotaT, TauraM, ShutoT, and KaiH. Podocyte p53 limits the severity of experimental alport syndrome. J Am Soc Nephrol, 27: 144–157, 2016.
12.
GrahammerF, SchellC, and HuberTB. The podocyte slit diaphragm—from a thin grey line to a complex signalling hub. Nat Rev Nephrol, 9: 587–598, 2013.
13.
GuoJ, AnanthakrishnanR, QuW, LuY, ReinigerN, ZengS, MaW, RosarioR, YanSF, RamasamyR, D'AgatiV, and SchmidtAM. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol, 19: 961–972, 2008.
14.
GuoZJ, NiuHX, HouFF, ZhangL, FuN, NagaiR, LuX, ChenBH, ShanYX, TianJW, NagarajRH, XieD, and ZhangX. Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal, 10: 1699–1712, 2008
15.
HuangCY, LeeCY, ChenMY, YangWH, ChenYH, ChangCH, HsuHC, FongYC, and TangCH. Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kappaB-dependent pathways. J Cell Physiol, 221: 204–212, 2009.
16.
HuangJ, LiY, TangY, TangG, YangGY, and WangY. CXCR4 antagonist AMD3100 protects blood-brain barrier integrity and reduces inflammatory response after focal ischemia in mice. Stroke, 44: 190–197, 2013.
17.
JeffersonJA and ShanklandSJ. The pathogenesis of focal segmental glomerulosclerosis. Adv Chronic Kidney Dis, 21: 408–416, 2014.
18.
JujoK, HamadaH, IwakuraA, ThorneT, SekiguchiH, ClarkeT, ItoA, MisenerS, TanakaT, KlyachkoE, KobayashiK, TongersJ, RoncalliJ, TsurumiY, HagiwaraN, and LosordoDW. CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarction. Proc Natl Acad Sci U S A, 107: 11008–11013, 2010.
KoshikawaM, MukoyamaM, MoriK, SuganamiT, SawaiK, YoshiokaT, NagaeT, YokoiH, KawachiH, ShimizuF, SugawaraA, and NakaoK. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol, 16: 2690–2701, 2005.
21.
KulbeH, HagemannT, SzlosarekPW, BalkwillFR, and WilsonJL. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res, 65: 10355–10362, 2005.
22.
LanX, ChengK, ChandelN, LedermanR, JhaveriA, HusainM, MalhotraA, and SinghalPC. High glucose enhances HIV entry into T cells through upregulation of CXCR4. J Leukoc Biol, 94: 769–777, 2013.
23.
LevoyeA, BalabanianK, BaleuxF, BachelerieF, and LaganeB. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood, 113: 6085–6093, 2009.
24.
LiHY, HouFF, ZhangX, ChenPY, LiuSX, FengJX, LiuZQ, ShanYX, WangGB, ZhouZM, TianJW, and XieD. Advanced oxidation protein products accelerate renal fibrosis in a remnant kidney model. J Am Soc Nephrol, 18: 528–538, 2007.
25.
LinCH, ShihCH, TsengCC, YuCC, TsaiYJ, BienMY, and ChenBC. CXCL12 induces connective tissue growth factor expression in human lung fibroblasts through the Rac1/ERK, JNK, and AP-1 pathways. PLoS One, 9: e104746, 2014.
26.
LiuB, HouX, ZhouQ, TianJ, ZhuP, XuJ, HouF, and FuN. Detection of advanced oxidation protein products in patients with chronic kidney disease by a novel monoclonal antibody. Free Radic Res, 45: 662–671, 2011.
27.
LiuSX, HouFF, GuoZJ, NagaiR, ZhangWR, LiuZQ, ZhouZM, ZhouM, XieD, WangGB, and ZhangX. Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb Vasc Biol, 26: 1156–1162, 2006.
28.
LotanD, SheinbergN, KopolovicJ, and DekelB. Expression of SDF-1/CXCR4 in injured human kidneys. Pediatr Nephrol, 23: 71–77, 2008.
29.
MaroniP, BendinelliP, MatteucciE, and DesiderioMA. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB. Carcinogenesis, 28: 267–279, 2007.
30.
MasudaT, NakashimaY, AndoK, YoshinagaK, SaekiH, OkiE, MoritaM, OdaY, and MaeharaY. Nuclear expression of chemokine receptor CXCR4 indicates poorer prognosis in gastric cancer. Anticancer Res, 34: 6397–6403, 2014.
31.
NagasawaT. CXCL12/SDF-1 and CXCR4. Front Immunol, 6: 301, 2015.
32.
NielsenJS and McNagnyKM. The role of podocalyxin in health and disease. J Am Soc Nephrol, 20: 1669–1676, 2009.
33.
O'BoyleG, SwidenbankI, MarshallH, BarkerCE, ArmstrongJ, WhiteSA, FrickerSP, PlummerR, WrightM, and LovatPE. Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070. Br J Cancer, 108: 1634–1640, 2013.
34.
PavenstadtH, KrizW, and KretzlerM. Cell biology of the glomerular podocyte. Physiol Rev, 83: 253–307, 2003.
35.
PhillipsRJ, MestasJ, Gharaee-KermaniM, BurdickMD, SicaA, BelperioJA, KeaneMP, and StrieterRM. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem, 280: 22473–22481, 2005.
36.
PlanavilaA, Redondo-AnguloI, RibasF, GarrabouG, CasademontJ, GiraltM, and VillarroyaF. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res, 106: 19–31, 2015.
37.
RaijL, AzarS, and KeaneWF. Role of hypertension in progressive glomerular immune injury. Hypertension, 7: 398–404, 1985.
38.
RehmanAO and WangCY. SDF-1alpha promotes invasion of head and neck squamous cell carcinoma by activating NF-kappaB. J Biol Chem, 283: 19888–19894, 2008.
39.
SchwartzmanM, ReginensiA, WongJS, BasgenJM, MeliambroK, NicholasSB, D'AgatiV, McNeillH, and CampbellKN. Podocyte-specific deletion of Yes-associated protein causes FSGS and progressive renal failure. J Am Soc Nephrol, 27: 216–226, 2016.
ShibataS, NagaseM, YoshidaS, KawachiH, and FujitaT. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension, 49: 355–364, 2007.
42.
SpeetjensFM, LiefersGJ, KorbeeCJ, MeskerWE, van de VeldeCJ, van VlierbergheRL, MorreauH, TollenaarRA, and KuppenPJ. Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients. Cancer Microenviron, 2: 1–7, 2009.
43.
StokmanG, QinY, BooijTH, RamaiahgariS, LacombeM, DolmanME, van DorenmalenKM, TeskeGJ, FlorquinS, SchwedeF, van de WaterB, KokRJ, and PriceLS. Epac-Rap signaling reduces oxidative stress in the tubular epithelium. J Am Soc Nephrol, 25: 1474–1485, 2014.
44.
SusztakK, RaffAC, SchifferM, and BöttingerEP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes, 55: 225–233, 2006.
45.
TanRJ, ZhouD, XiaoL, ZhouL, LiY, BastackySI, OuryTD, and LiuY. Extracellular superoxide dismutase protects against proteinuric kidney disease. J Am Soc Nephrol, 26: 2447–2459, 2015.
46.
TanY, LiY, XiaoJ, ShaoH, DingC, ArteelGE, WebsterKA, YanJ, YuH, CaiL, and LiX. A novel CXCR4 antagonist derived from human SDF-1beta enhances angiogenesis in ischaemic mice. Cardiovasc Res, 82: 513–521, 2009.
47.
WagnerN, WagnerKD, XingY, ScholzH, and SchedlA. The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1. J Am Soc Nephrol, 15: 3044–3051, 2004.
48.
WangY, WangYP, TayYC, and HarrisDC. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int, 58: 1797–1804, 2000.
49.
WeiXF, ZhouQG, HouFF, LiuBY, and LiangM. Advanced oxidation protein products induce mesangial cell perturbation through PKC-dependent activation of NADPH oxidase. Am J Physiol Renal Physiol, 296: F427–F437, 2009.
50.
XiaoL, ZhouD, TanRJ, FuH, ZhouL, HouFF, and LiuY. Sustained activation of Wnt/β-catenin signaling drives AKI to CKD progression. J Am Soc Nephrol, 27: 1727–1740, 2016.
51.
YouYH, QuachT, SaitoR, PhamJ, and SharmaK. Metabolomics reveals a key role for fumarate in mediating the effects of NADPH oxidase 4 in diabetic kidney disease. J Am Soc Nephrol, 27: 466–481, 2016.
52.
ZhengS, CarlsonEC, YangL, KralikPM, HuangY, and EpsteinPN. Podocyte-specific overexpression of the antioxidant metallothionein reduces diabetic nephropathy. J Am Soc Nephrol, 19: 2077–2085, 2008.
53.
ZhouLL, CaoW, XieC, TianJ, ZhouZ, ZhouQ, ZhuP, LiA, LiuY, MiyataT, HouFF, and NieJ. The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int, 82: 759–770, 2012.
54.
ZhouLL, HouFF, WangGB, YangF, XieD, WangYP, and TianJW. Accumulation of advanced oxidation protein products induces podocyte apoptosis and deletion through NADPH-dependent mechanisms. Kidney Int, 76: 1148–1160, 2009.
55.
ZhouL, LiY, HaoS, ZhouD, TanRJ, NieJ, HouFF, KahnM, and LiuY. Multiple genes of the renin-angiotensin system are novel targets of Wnt/β-catenin signaling. J Am Soc Nephrol, 26: 107–120, 2015.
56.
ZhouL, LiY, HeW, ZhouD, TanRJ, NieJ, HouFF, and LiuY. Mutual antagonism of Wilms' tumor 1 and β-catenin dictates podocyte health and disease. J Am Soc Nephrol, 26: 677–691, 2015.
57.
ZhouL and LiuY. Wnt/β-catenin signalling and podocyte dysfunction in proteinuric kidney disease. Nat Rev Nephrol, 11: 535–545, 2015.
58.
ZhouL, MoH, MiaoJ, ZhouD, TanRJ, HouFF, and LiuY. Klotho ameliorates kidney injury and fibrosis and normalizes blood pressure by targeting the renin-angiotensin system. Am J Pathol, 185: 3211–3223, 2015.
59.
ZukA, GershenovichM, IvanovaY, MacFarlandRT, FrickerSP, and LedbetterS. CXCR(4)antagonism as a therapeutic approach to prevent acute kidney injury. Am J Physiol Renal Physiol, 307: F783–F797, 2014.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
